Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Other 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Pheochromocytoma 2Neuroblastoma 2Thyroid Carcinoma, Anaplastic 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Head and Neck Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Paclitaxel 4fosbretabulin 3Radiotherapy 3selpercatinib 2Filgrastim 2Everolimus 2Doxorubicin 2Cisplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1sargramostim 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1mercaptoundecahydrododecaborate 1gallium Ga 68 dotatate 1fostamatinib 1entrectinib 1combretastatin 1alectinib 1aldesleukin 1Triiodothyronine 1Thyrotropin Alfa 1Thyrotropin 1Thalidomide 1Tamoxifen 1Semaxinib 1Rosiglitazone 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × pegfilgrastim × Endocrine × Clear all
NCT00077103 2010-06-11

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Case Comprehensive Cancer Center

Phase 1/2 Terminated
4 enrolled
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡